SCHEMBL631669

SCHEMBL631669

CCCC(O)(CCC)c1ccccc1N

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.37
CNR2 P34972 1/20 0.37
CYP2C19 P33261 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
ALDH1A1 P00352 6/20 0.35
ALOX15 P16050 2/20 0.35
CYP3A4 P08684 2/20 0.35
CASP1 P29466 1/20 0.35
CASP7 P55210 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HSD17B10 Q99714 4/20 0.34
ESR1 P03372 2/20 0.34
GAA P10253 1/20 0.34
ALOX12 P18054 1/20 0.34
TSHR P16473 1/20 0.33
FDPS P14324 1/20 0.33
NOS3 P29474 2/20 0.33
NOS1 P29475 2/20 0.33
NOS2 P35228 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19209998 0.86 CNR1 (0.33) CNR1CNR2CYP2C19CYP1A2CYP2C9
SCHEMBL647668 0.84 HSP90AA1 (0.38) CNR1CNR2CYP2C19CYP1A2CYP2C9
SCHEMBL2076194 0.83 ALDH1A1 (0.38) CNR1CNR2CYP2C19CYP1A2CYP2C9
SCHEMBL15873882 0.82 ALDH1A1 (0.37) CNR1CNR2CYP2C19ALDH1A1SMN1; SMN2
SCHEMBL12971341 0.78 CYP1A2 (0.37) CNR1CNR2CYP2C19CYP1A2CYP2C9
SCHEMBL12680688 0.78 ALDH1A1 (0.45) CYP2C19CYP1A2CYP2C9ALDH1A1CYP3A4
SCHEMBL6470377 0.78 CNR1 (0.38) CNR1CNR2CYP2C19CYP1A2CYP2C9
SCHEMBL11160450 0.77 NOS3 (0.32) CNR1CNR2CYP2C19CYP1A2CYP2C9
SCHEMBL2443511 0.75 ALDH1A1 (0.38) CYP2C19CYP1A2CYP2C9ALDH1A1ALOX15
SCHEMBL31328394 0.74 GABRA1 (0.34) CYP2C19ALDH1A1ESR1GAAALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1901776-B1 NOVEL MEDICINAL COMBINATIONS WHICH ARE USED FOR TREATING RESPIRATORY TRACT DISEASES AND CONTAIN BETA-2 LONG-ACTING AGONISTS AND AT LEAST ONE OTHER TYPE OF ACTIVE SUBSTANCE BOEHRINGER INGELHEIM INT (DE) 2012-02-22 EP disclosed
EP-1856070-B1 NOVEL DRUGS FOR TREATING RESPIRATORY DISEASES BOEHRINGER INGELHEIM INT (DE) 2011-07-27 EP disclosed
US-20110053926-A1 New Pharmaceutically-Active Compounds for the Treatment of Respiratory Diseases BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-03-03 US disclosed
EP-1911749-B1 New long-working Beta-2 agonists and their use as medicine BOEHRINGER INGELHEIM INT (DE) 2010-10-27 EP disclosed
US-20100233268-A1 POWDER FORMULATIONS FOR INHALATION CONTAINING ENANTIOMERICALLY PURE BETA-AGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-16 US disclosed
US-7709474-B2 Enantiomerically pure beta agonists, manufacturing and use thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-05-04 US disclosed
US-7632834-B2 Long acting beta-2-agonists and their use as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-12-15 US disclosed
EP-2094271-A2 DRUG COMBINATIONS FOR TREATING AIRWAY DISEASES Boehringer Ingelheim International GmbH (DE) 2009-09-02 EP disclosed
EP-2056836-A1 POWDER FORMULATIONS FOR INHALATION CONTAINING ENANTIOMERICALLY PURE BETA-AGONISTS Boehringer Ingelheim International GmbH (DE) 2009-05-13 EP disclosed
EP-2057134-A1 SINGLE ENANTIOMER BETA AGONISTS METHOD FOR PRODUCTION AND USE THEREOF AS A MEDICAMENT Boehringer Ingelheim International GmbH (DE) 2009-05-13 EP disclosed
EP-1856070-A1 NOVEL DRUGS FOR TREATING RESPIRATORY DISEASES Boehringer Ingelheim International GmbH (DE) 2007-11-21 EP disclosed
US-20070066609-A1 Long acting beta-2-agonists and their use as medicaments BOUYSSOU THIERRY 2007-03-22 US disclosed
US-20070037781-A1 Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-02-15 US disclosed
WO-2007003554-A1 NOVEL MEDICINAL COMBINATIONS WHICH ARE USED FOR TREATING RESPIRATORY TRACT DISEASES AND CONTAIN BETA-2 LONG-ACTING AGONISTS AND AT LEAST ONE OTHER TYPE OF ACTIVE SUBSTANCE. BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-01-11 WO disclosed
US-7160882-B2 Long acting β-2-agonists and their use as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-01-09 US disclosed
EP-1711480-A1 NOVEL LONG-WORKING BETA-2-AGONISTS AND USE THEREOF AS MEDICAMENTS Boehringer Ingelheim International GmbH (DE) 2006-10-18 EP disclosed
WO-2006089859-A1 NOVEL DRUGS FOR TREATING RESPIRATORY DISEASES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-08-31 WO disclosed
US-20060189605-A1 NEW PHARMACEUTICALLY-ACTIVE COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-08-24 US disclosed
US-20050227975-A1 New long acting beta-2-agonists and their use as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-10-13 US disclosed
WO-2005070908-A1 NOVEL LONG-WORKING BETA-2-AGONISTS AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070066609-A1 Long acting beta-2-agonists and their use as medicaments ADRB2, ADRB1, CHRM1 CNR1 15/4885CNR2 10/4885CYP2C19 1380/4885
US-20050227975-A1 New long acting beta-2-agonists and their use as medicaments ADRB2, ADRA2A, ADRB1 CNR1 126/4885CNR2 70/4885CYP2C19 1381/4885
US-20100233268-A1 POWDER FORMULATIONS FOR INHALATION CONTAINING ENANTIOMERICALLY PURE BETA-AGONISTS ADRB2, ADRB3, ADRB1 CNR1 68/4885CNR2 70/4885CYP2C19 469/4885
US-20070037781-A1 Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient ADRB2, ADRA2A, ADRB1 CNR1 274/4885CNR2 234/4885CYP2C19 3479/4885
US-20060189605-A1 NEW PHARMACEUTICALLY-ACTIVE COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES CFTR, SDHA, HRH1 CNR1 211/4885CNR2 466/4885CYP2C19 82/4885
US-20110053926-A1 New Pharmaceutically-Active Compounds for the Treatment of Respiratory Diseases CFTR, SDHA, HRH1 CNR1 211/4885CNR2 466/4885CYP2C19 82/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.